We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

PerkinElmer to Acquire Oxford Immunotec Global PLC

By LabMedica International staff writers
Posted on 08 Jan 2021
Print article
Illustration
Illustration
PerkinElmer, Inc. (Waltham, MA; USA) has reached an agreement to acquire Oxford Immunotec Ltd. (Abingdon, UK) that will allow the company to grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection.

The deal will enable PerkinElmer to combine its channel expertise and leading workflow and testing capabilities with Oxford Immunotec’s leading proficiencies in T cell immunology with its proprietary test kits for latent tuberculosis. Oxford Immunotec is the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. The company’s T-SPOT.TB test is used for diagnosing infection with tuberculosis and it has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the US, where it has received pre-market approval from the FDA, Europe, where it has obtained a CE mark, as well as Japan and China.

“Tuberculosis remains one of the leading infectious causes of death, with close to one quarter of the world’s population infected,” said Prahlad Singh, PhD, President and Chief Executive Officer of PerkinElmer. “We believe Oxford Immunotec’s diagnostic testing solution plays an important role in slowing the spread and saving lives. Oxford Immunotec’s highly sensitive test and their team’s passion for solving complex health issues make it a natural fit with PerkinElmer’s mission and together, we believe will accelerate development of robust solutions to help detect infectious disease.”

“We are delighted to be joining the PerkinElmer family. We believe this transaction is great for our shareholders, our employees and our customers,” said Peter Wrighton-Smith, PhD, Chief Executive Officer of Oxford Immunotec. “Access to PerkinElmer’s global reach and automation experience will enable us to accelerate our growth journey and make a growing impact in the field of infectious disease.”




Gold Supplier
Streptococcus Test
STREPA’LERT
New
Gold Supplier
Tumor Marker Control
Tumor Marker Control
Silver Supplier
SARS-CoV-2 RT-PCR Assay
ErbaMDx SARS-COV-2 RT-PCR Kit
COVID-19 Anitibody Test
TGS COVID-19 IgG

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis (Photo courtesy of Dr. Christopher Wiley)

Novel Lipid Biomarker Detects Senescent Cells

A recent paper identified a lipid biomarker indicative of cellular senescence and described a method to evaluate its effect on the molecular events that lead to senescence. Cellular senescence is a... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.